Which Topical Steroid is Better for Eosinophilic Esophagitis?
Both fluticasone and budesonide are equally effective for treating eosinophilic esophagitis, but budesonide orodispersible tablets (where available) or oral viscous budesonide should be preferred due to regulatory approval, superior drug delivery to the esophagus, and potentially better histologic outcomes. 1, 2
Evidence-Based Reasoning
Guideline Recommendations
The 2020 AGA/JTF guidelines and 2022 British Society of Gastroenterology guidelines both strongly recommend topical glucocorticosteroids for EoE but do not definitively favor one agent over the other 1. However, the guidelines note important distinctions:
- Budesonide orodispersible tablets received regulatory approval from the European Medicines Agency in 2018 for EoE treatment 1
- Eight pooled RCTs (437 patients) showed topical steroids reduced histologic remission failure with RR 0.39 (95% CI 0.26-0.58) compared to placebo, but studies included both budesonide and fluticasone with varying formulations 1
- The British guidelines specifically support orodispersible budesonide over other swallowed steroid formulations for adults given its regulatory approval 2
Direct Comparison Studies
The highest quality head-to-head comparison is a 2019 double-blind RCT that directly compared oral viscous budesonide (OVB) versus fluticasone MDI 3:
- No significant difference in efficacy: Post-treatment eosinophil counts were 15 vs 21 eos/hpf (p=0.31)
- Histologic response rates: 71% (OVB) vs 64% (fluticasone), p=0.38
- Dysphagia scores improved similarly in both groups (p=0.70)
- Conclusion: Either agent is acceptable; OVB was not superior to fluticasone MDI 3
However, a 2018 pediatric retrospective study showed budesonide may have an edge:
- Histologic response: 75% (OVB) vs 40% (fluticasone), p=0.0059
- Greater reduction in eosinophil counts with OVB (p=0.002) 4
Meta-Analysis Data
A 2021 meta-analysis of 9 RCTs (483 patients) found 5:
- Budesonide: RR 13.5 for histologic remission
- Fluticasone: RR 10.4 for histologic remission
- Orodispersible tablet formulation showed best results (RR 46.2) compared to suspension (11.5) or nebulized formula (10.4)
- Clinical response was less impressive overall: significant differences in only 4/6 budesonide studies vs 0/3 fluticasone studies
Practical Clinical Algorithm
For Adult Patients:
- First choice: Budesonide orodispersible tablet (1 mg BID for induction) if available and affordable 2, 6
- Alternative: Oral viscous budesonide (1 mg/4 mL BID) - equally effective, requires compounding 3
- Budget-conscious option: Fluticasone MDI (880 mcg BID) - off-label but effective and widely available 3
For Pediatric Patients:
- Oral viscous budesonide: 1 mg/day if <150 cm height, 2 mg/day if >150 cm 2
- Fluticasone MDI: 110 mcg/puff (age <10) or 220 mcg/puff (age 11-18), 2 puffs 4 times daily 1
Important Caveats
Safety Profile is Similar:
- Esophageal candidiasis: 12% (budesonide) vs 16% (fluticasone) 3
- Oral thrush: 3% vs 2% respectively 3
- No increased adverse events vs placebo in short-term studies (RR 1.0,95% CI 0.85-1.19) 1
- Adrenal suppression rare but monitor in children on long-term therapy 2
Treatment Duration Matters:
- Induction: 6-12 weeks minimum 2
- Maintenance required: 73-75% maintain remission on budesonide 0.5-1 mg BID vs 4.4% on placebo 2
- Relapse rates high (45%) if treatment stopped 1
Formulation is Critical:
- Drug must coat the esophageal mucosa - patients should not eat or drink for 30 minutes after administration
- Swallowed (not inhaled) administration essential
- Viscous preparations or orodispersible tablets superior to standard inhalers for esophageal delivery 5
The bottom line: While both agents work, budesonide formulations designed for esophageal delivery (orodispersible tablets or oral viscous preparations) offer the best evidence for efficacy, though fluticasone MDI remains a reasonable and cost-effective alternative when budesonide is unavailable or unaffordable. 3, 5